Focal Seizures and Subependymal Nodules in a Patient with Tuberous Sclerosis Complex: A Case Report with a Positive Genetic Testing

CASE REPORT
Valbona Govori, Bujar Gjikolli, Elsa Berisha, Naim Zeka

 
For citation: Govori V, Gjikolli B, Berisha E, Zeka N. Focal Seizures and Subependymal Nodules in a Patient with Tuberous Sclerosis Complex: A Case Report with a Positive Genetic Testing. International Journal of Biomedicine. 2025;15(2):411-415. doi:10.21103/Article15(2)_CR3
 
Originally published June 5, 2025
 

Abstract: 

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder causing non-malignant tumors in various organs. This case report details a 5-month-old infant admitted for recurrent focal seizures characterized by rhythmic jerking of the left limbs and head deviation. Physical examination revealed hypopigmented macules, while brain MRI showed subependymal nodules and subcortical lesions. Cardiac rhabdomyomas were detected via echocardiography. Genetic testing confirmed a pathogenic TSC2 mutation. Despite the vigabatrin treatment, seizure control was partial. Long-term antiseizure therapy and follow-up remain essential for management. Further studies are needed to explore factors influencing therapeutic efficacy. 

Keywords: 
rhabdomyoma • case reports • seizures • genetic testing • tuberous sclerosis
References: 
  1. Borkowska J, Schwartz RA, Józwiak S. Recent perspectives on diagnosis and treatment of tuberous sclerosis complex in children. International Journal on Disability and Human Development. 2009;8(4). doi:10.1515/ijdhd.2009.8.4.369
  2. Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, Sahin M, Kwiatkowski DJ. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015 Nov 5;11(11):e1005637. doi: 10.1371/journal.pgen.1005637. PMID: 26540169; PMCID: PMC4634999.
  3. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010 Jan;1184:87-105. doi: 10.1111/j.1749-6632.2009.05117.x. PMID: 20146692; PMCID: PMC2892799.
  4. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, Jansen AC, Jóźwiak S, Kingswood JC, Knilans TK, McCormack FX, Pounders A, Roberds SL, Rodriguez-Buritica DF, Roth J, Sampson JR, Sparagana S, Thiele EA, Weiner HL, Wheless JW, Towbin AJ, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021 Oct;123:50-66. doi: 10.1016/j.pediatrneurol.2021.07.011. Epub 2021 Jul 24. PMID: 34399110.
  5. Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado MCDM. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol. 2018 Jun;93(3):323-331. doi: 10.1590/abd1806-4841.20186972. PMID: 29924239; PMCID: PMC6001077.
  6. Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA consortium and TOSCA investigators. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017 Jan 5;12(1):2. doi: 10.1186/s13023-016-0553-5. PMID: 28057044; PMCID: PMC5217262.
  7. Wataya-Kaneda M, Uemura M, Fujita K, Hirata H, Osuga K, Kagitani-Shimono K, Nonomura N; Tuberous Sclerosis Complex Board of Osaka University Hospital. Tuberous sclerosis complex: Recent advances in manifestations and therapy. Int J Urol. 2017 Sep;24(9):681-691. doi: 10.1111/iju.13390. Epub 2017 Jul 1. PMID: 28667702.
  8. Singh A, Hadjinicolaou A, Peters JM, Salussolia CL. Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions. Neuropsychiatr Dis Treat. 2023 Apr 5;19:733-748. doi: 10.2147/NDT.S347327. PMID: 37041855; PMCID: PMC10083014.
  9. Flotats-Bastardas M, Ebrahimi-Fakhari D, Gortner L, Poryo M, Zemlin M, Macaya-Ruiz A, Meyer S. Diagnosis and Treatment of Tuberous Sclerosis Manifestations in Children: A Multicenter Study. Neuropediatrics. 2018 Jun;49(3):193-199. doi: 10.1055/s-0038-1637738. Epub 2018 Mar 20. PMID: 29558773.
  10. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010 Jul;51(7):1236-41. doi: 10.1111/j.1528-1167.2009.02474.x. Epub 2009 Dec 22. PMID: 20041940; PMCID: PMC3065368.
  11. Hussain SA, Schmid E, Peters JM, Goyal M, Bebin EM, Northrup H, Sahin M, Krueger DA, Wu JY; Tuberous Sclerosis Complex Autism Center of Excellence Network. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Res. 2018 Dec;148:1-7. doi: 10.1016/j.eplepsyres.2018.09.016. Epub 2018 Oct 2. PMID: 30296632; PMCID: PMC6347124.
  12. Lin S, Liao J, Zhao X, Hu Y, Chen L, Chen Y, Liu G, Yao Y, Su Q, Scheffer IE, Wen F. Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? J Child Neurol. 2022 Apr;37(5):329-333. doi: 10.1177/08830738211048326. Epub 2022 Mar 23. PMID: 35321578.
  13. Specchio N, Nabbout R, Aronica E, Auvin S, Benvenuto A, de Palma L, Feucht M, Jansen F, Kotulska K, Sarnat H, Lagae L, Jozwiak S, Curatolo P. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. Eur J Paediatr Neurol. 2023 Nov;47:25-34. doi: 10.1016/j.ejpn.2023.08.005. Epub 2023 Aug 30. Erratum in: Eur J Paediatr Neurol. 2024 Jul;51:149-150. doi: 10.1016/j.ejpn.2023.12.004. PMID: 37669572.
  14. Mammadova D, Vecko J, Hofmann M, Schüssler SC, Deiters L, Canda A, Wieland AK, Gollwitzer S, Hamer H, Trollmann R. A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex. Orphanet J Rare Dis. 2023 Nov 9;18(1):349. doi: 10.1186/s13023-023-02959-0. PMID: 37946245; PMCID: PMC10637019.
  15. Pearsson K, Eklund EA, Rask O, Rosén I, Sjunnesson H, Compagno-Strandberg M. The evolution of epilepsy surgery in tuberous sclerosis in Sweden: A national registry study. Seizure. 2023 Nov;112:54-61. doi: 10.1016/j.seizure.2023.09.016. Epub 2023 Sep 16. PMID: 37757549.
  16. Al Kindi HN, Ibrahim AM, Roshdy M, Abdelghany BS, Yehia D, Masoud AN, Simry W, Aguib Y, Yacoub MH. Clinical, cellular, and molecular characterisation of cardiac rhabdomyoma in tuberous sclerosis. Cardiol Young. 2021 Aug;31(8):1297-1305. doi: 10.1017/S1047951121000172. Epub 2021 Feb 19. PMID: 33602381.
  17. Pearsson K, Björk Werner J, Lundgren J, Gränse L, Karlsson E, Källén K, Eklund EA, Bekassy Z. Childhood tuberous sclerosis complex in southern Sweden: a paradigm shift in diagnosis and treatment. BMC Pediatr. 2023 Jun 29;23(1):329. doi: 10.1186/s12887-023-04137-4. PMID: 37386496; PMCID: PMC10308728.
  18. Yeşil Ş, Kurucu B, Hamamcı MB, Yılmaz Ş, Şahin G. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors. Childs Nerv Syst. 2024 Mar;40(3):831-837. doi: 10.1007/s00381-023-06218-2. Epub 2023 Nov 10. PMID: 37947859.
  19. Pounders AJ, Rushing GV, Mahida S, Nonyane BAS, Thomas EA, Tameez RS, Gipson TT. Racial differences in the dermatological manifestations of tuberous sclerosis complex and the potential effects on diagnosis and care. Ther Adv Rare Dis. 2022 Dec 10;3:26330040221140125. doi: 10.1177/26330040221140125. PMID: 37180419; PMCID: PMC10032467.
  20. Dao DD, Pixley JN, Akkurt ZM, Feldman SR. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex. Ann Pharmacother. 2024 Apr;58(4):428-433. doi: 10.1177/10600280231182421. Epub 2023 Jun 29. PMID: 37386842.

Download Article
Received January 28, 2025.
Accepted March 9, 2025.
©2025 International Medical Research and Development Corporation.